Borchmann P, Goergen H, Kobe C, et al. Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim PET: final results of the international, randomized phase 3 trial HD18 by the German Hodgkin Study Group. EHA 2017, abstract S150.
Isatuximab, carfilzomib en dexamethason bij gerecidiveerd multipel myeloom (IKEMA)
aug 2021 | MM